Trial Profile
Comparison Between Lamivudine and Entecavir Treatment in Patients With Spontaneous Severe Acute Exacerbation of Chronic Hepatitis B.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Lamivudine (Primary) ; Entecavir
- Indications Hepatitis B
- Focus Therapeutic Use
- 22 Apr 2016 Status changed from recruiting to discontinued due to slow progress in recruiting study patients.
- 29 Jun 2012 New trial record